Overview

Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2015-11-04
Target enrollment:
Participant gender:
Summary
SPIL1033 resembles a gut hormone, which increases the insulin secretion, thus helps in reducing blood glucose levels. The purpose of study is to establish safety and efficacy of SPIL1033
Phase:
Phase 3
Details
Lead Sponsor:
Sun Pharmaceutical Industries Limited